Paediatric acute disseminated encephalomyelitis followed by optic neuritis: disease course, treatment response and outcome by Wong, YYM et al.
Paediatric ADEM followed by optic neuritis: disease course, treatment 
response and outcome 
YYM Wong MD1, Y Hacohen MD,PhD2,3, T Armangue MD,PhD4,5, E Wassmer 
MD,PhD6, H Verhelst MD,PhD7, C Hemingway MD,PhD3, ED van Pelt MD,PhD1, CE 
Catsman-Berrevoets MD,PhD 8, RQ Hintzen MD,PhD 1, K Deiva MD,PhD 9,10*, MJ 
Lim MD,PhD 11,12*, K Rostásy MD,PhD 13*, RF Neuteboom MD,PhD 9*. 
1. Department of Neurology, Erasmus MC, Rotterdam, The Netherlands 
2. Department of Neuroinflammation, Queen Square MS Centre, UCL Institute of 
Neurology, London, UK 
3. Department of Paediatric Neurology, Great Ormond Street Hospital for 
Children, London, UK 
4. Neuroimmunology Program, IDIBAPS- Hospital Clínic- Universistat de 
Barcelona, Barcelona, Spain 
5. Paediatric Neuroimmunology Unit, Service of Neurology, Sant Joan de Déu 
Children’s Hospital, Universitat de Barcelona, Barcelona, Spain. 
6. Department of Paediatric Neurology, Birmingham Children’s Hospital, London, 
UK 
7. Department of Paediatrics, Division of Paediatric Neurology, Ghent University 
Hospital, Ghent, Belgium 
8. Department of Paediatric Neurology, Erasmus MC, Rotterdam, The 
Netherlands 
9. Department of Paediatric Neurology, Assistance Publique-Hôpitaux de Paris, 
Hôpital Bicêtre, National Referral Centre for Neuro-Inflammatory Diseases in 
Children, Paris, France 
10. University Paris Sud, Le Kremlin-Bicêtre, Paris, France 
11. Children’s Neurosciences, Evelina London Children's Hospital at Guy's and St 
Thomas' NHS Foundation Trust, King’s Health Partners Academic Health 
Science Centre, London, UK 
12. Faculty of Life Sciences and Medicine, King’s College London, UK 
13. Department of Paediatric Neurology, Children’s Hospital Datteln, University 
Witten/Herdecke, Germany 
*Joint senior authors 
Word count:  2621 
Abstract:  195     
References:  15 
Tables:  1   
Figures:  1 
 
Running title: children with ADEM followed by optic neuritis  
 
Key words: acute disseminated encephalomyelitis, optic neuritis, anti-MOG 
antibodies, paediatric, treatment response 
Corresponding author: 
R.F. Neuteboom, MD, PhD 
Erasmus MC-Sophia, Room SK-1214 
PO Box 2060 
3000 CB Rotterdam  
The Netherlands 
Tel. +31 107036956 







Background: Acute disseminated encephalomyelitis, followed by optic neuritis 
(ADEM-ON) is a rare demyelinating syndrome different than MS and neuromyelitis 
optica spectrum disorder. We aim to describe the disease course, treatment 
response and outcome of these children.  
Methods: children <18 years were identified from 6 countries of the EU Paediatric 
Demyelinating Disease Consortium. Patients fulfilled the diagnostic criteria for ADEM, 
followed by at least one ON. Anti-MOG antibodies (MOG-Ab) were tested in all 
patients.  
Results: in this study of 17 patients (9 boys) with ADEM-ON, MOG-ab were identified 
in 16/17. Age at onset was 6.1 years (IQR 5.1-9.2). Twelve patients received oral 
prednisolone and 10 received maintenance immunosuppression (e.g. azathioprine, 
intravenous immunoglobulins, Rituximab). During a follow-up of 5.3 years (IQR 1.8-
10.2), 54 relapses occurred with a median 3 relapses/patient (range 1-9). Patients 
relapsed on all treatments but no relapses occurred on a prednisolone 
dose>10mg/day. Visual and cognitive residual deficits were common in this group.   
Conclusion: ADEM-ON is a MOG-Ab associated relapsing disorder and can have a 
heterogeneous disease course. Patients were refractory for maintenance 
immunosuppression and appeared to be corticosteroid-dependent. Further 
international collaborations are now required to unify guidelines in this difficult to 




Acute disseminated encephalomyelitis (ADEM) is a well-recognized acquired 
demyelinating syndrome (ADS) characterized by a polyfocal onset and 
encephalopathy. It is most commonly seen in young children.[1] Although 
predominantly monophasic, some children relapse and may fulfill the diagnostic 
criteria of multiple sclerosis (MS) or neuromyelitis optica spectrum disorders 
(NMOSD).[1] More recently, a distinct clinical phenotype has been recognized, 
different than MS and NMOSD, with patients relapsing with single or recurrent 
episode of ON following ADEM.[2] The majority of these children have myelin 
oligodendrocyte glycoprotein antibodies (MOG-Ab). [3-5] In a Dutch paediatric cohort 
of acquired demyelinating syndrome (ADS) only 1.2% of children were diagnosed 
with ADEM-ON.[6] Despite the rarity of ADEM-ON in ADS, ADEM-ON has been the 
final diagnosis in about 40% of MOG-ab positive relapsing patients who initially 
presented with ADEM.[7]  
As no treatment guidelines are currently available for patients with ADEM-ON the aim 
of this European collaboration study was to  escribe the disease course, treatment 
response and outcome of ADEM-ON patients in a multinational approach.  
PATIENTS AND METHODS 
Data collection 
We collected demographic, clinical, radiological and serological data of 17 patients 
under age 18 from 6 countries of the EU Paediatric Demyelinating Disease 
Consortium (The Netherlands n=7, United Kingdom n=6, Germany n=1, France n=1, 
Spain n=1, Belgium n=1). This consortium was initiated as a component of the ERN-
RITA (European Reference Network for Rare Immunodeficiency, Autoinflammatory 
and Autoimmune Disease). Patients were identified by reviewing local or national 
paediatric demyelination registries and included after fulfilling the following criteria: i) 
presenting with ADEM as a first demyelinating event in accordance with the IPMSSG 
criteria ii) experiencing ≥1 subsequent attack of optic neuritis (ON) without 
encephalopathy ≥3 months after ADEM onset, with or without additional episodes of 
ADEM in between (MDEM-ON).[1]  
 
A unified case reporting form was distributed to all participating sites to collect de-
identified patient data. Assessments of visual function were carried out by 
ophthalmology departments at the respective centres, including high contrast visual 
acuity measured by the logarithm of the minimum angle of resolution (logMAR) and 
colour vision measured by Ishihara plates.  
All patients were tested locally in the respective reference laboratories of the referring 
countries for serum MOG and AQP4 antibodies, using live cell-based assays, as part 
of standard clinical care while clinically symptomatic.[3, 4, 8-10]  
Institutional review board and/or national research ethics approval was obtained at 
individual centers or national programs respectively.  
 
STATISTICAL ANALYSIS 
Chi square and Mann-Whitney U test were used for group comparison. Time to first 
ON-relapse (TTFR) was calculated by subtracting the date of ON-relapse from the 
onset date of the last ADEM attack. ARR after the first ON was analyzed with a 
negative binomial regression, with the natural logarithm of follow-up years after the 
first ON as offset. This offset was used to correct for the different follow-up durations 
between patients. Statistical significance was set at p-value of 0.05.  
RESULTS 
Seventeen ADEM-ON patients were included in this study. Clinical, paraclinical 
features, treatment response and outcome are summarised in Table 1 and Figure 1. 
MOG-Ab were identified in 16/17 (94%). This seronegative patient had a typical 
ADEM-ON disease course and serum was tested in the acute phase at onset and re-
tested during relapses. MOG-ab were persistently positive in all patients who were 
retested at follow-up (n=8) irrespective of the presence of disease activity. All 
patients were AQP4-Ab negative. Brain MRI at follow-up showed improvement or 
complete resolution of ADEM brain lesions in all patients.  
A total of 54 relapses were reported in the cohort (median 3 relapses per patient, 
range 1-9), during a median follow-up of 5.3 years (IQR 1.8-10.2). Of which 
51/54(94.4%) were ON (10/51 bilateral) and 3/54(5.6%) ADEM-relapses (Figure 1). 
Nadir visual acuity (VA) at relapses (n=32) was median 0.08 (IQR <1/300 – 0.38). No 
differences in nadir VA or residual deficits was observed between treated and 
untreated patients.  Oral prednisolone taper was used in 12/17 (70.6%) patients 
starting dose 1-2 mg/kg/day). Twenty-seven of the 54 relapses occurred when oral 
corticosteroids were tapered off to a low dose (median 8.5 mg, range 1-10 mg) or in 
the four weeks following discontinuation (median 1.1 weeks; range 0.5-5 weeks). 
Oral corticosteroid was re-introduced using a higher dose when relapse occurred 
(median 20 mg, range 10-60 mg), resulting in prolonged corticosteroid exposure 
(median 6 months, IQR 1.7-14.8 months). No relapses occurred while using a 
dose>10mg. 
Maintenance immunotherapy was commenced in 10/17(59%); Azathioprine 2-3 
mg/kg/day (n=6), Mycophenolate 1200 mg/m2/day (n=1), regular IVIG 0.4-1.0 
g/kg/dosis (n=2) and Cyclophosphamide 750 mg/m2/month for 6 months (n=1). 
Median time from acute treatment to initiating maintenance therapy was 3 days 
(range 0-42 days). Treatment response was evaluated at least 6 months after 
initiation (time of treatment range 6-61 months). Six patients relapsed on 
maintenance treatment (total 13 relapses) and were switched to another therapy or 
another agent was added to the treatment regime, including Rituximab (500 
mg/m2/dosis, 2 dosis per cycle; every 6 months) and IviG (Figure 1). Of these 6/13 
relapses occurred when the oral corticosteroids were tapered off to a low dose (≤10 
mg/day) despite ≥6 months of treatment with maintenance therapy. Seven relapses 
occurred in patients on maintenance treatment only. The disease course differed 
between patients in the annual relapse rate and interattack duration (median 5.7 
months, range 3-247 months), in both treated and untreated patients (Figure 1).  
A shorter TTFR was associated with more relapses after the first ON during follow-up 
(spearman rho -0.531,p=0.028). The median TTFR was 7months(IQR 4-85). There 
was a trend to have higher ARR in patients who relapsed within 7months (mean ARR 
1.24 vs 0.35,p=0.061).  
At last follow-up, residual deficits were reported in 12/17(71%) patients and included  
visual impairments (n=8), cognitive impairments (n=8), seizures (n=2), behavioural 
problems (n=3), weakness in extremities (n=1) and bladder/bowel dysfunction (n=1) 
were less common. The median EDSS score at last follow-up was 1.0 (IQR 0-3.0).  




Here we report the disease course, treatment and outcome of ADEM-ON patients 
identified from six European countries. MOG-Ab were identified in 16/17. This rare 
group of patients was characterized by large heterogeneity in disease course and 
applied treatment regimens. By contrast to the reported literature in adults with MOG-
Ab associated disease, residual deficits such as visual and cognitive impairments 
were common.[10-14]  
Despite heterogeneity in treatment we observed that relapses occurred on all 
treatments even under more potent therapies such as Rituximab and/or IVIG. Oral 
prednisone, on the contrary, was effective if given in doses >10mg daily. This 
indicates a certain degree of corticosteroid dependence in these children, although 
the worrisome side effects and unpredictable disease course of ADEM-ON patients 
warrant against long-term use of high doses (>10mg) prednisone. Corticosteroid 
dependence may be typical for relapsing MOG-Ab relapsing ON.[15]  
We observed a prolonged interattack intervals (>5 years) which is not typically seen 
in children with RRMS and may result in potential overtreatment and exposure to 
long-term immunosuppression. This stresses the importance of identifying early 
predictors for future disease course. TTFR may be good marker, as children with a 
short TTFR tended to have a higher ARR. Monitoring of MOG-Ab during the course 
of disease may aid in predicting the future disease course and guiding treatment.[16]   
Although this study was the result of a multinational EU collaboration, the sample 
size remained relatively small due to the extreme rarity of ADEM-ON. Some patients 
with solely one ON-relapse within the first three months of ADEM were excluded as 
we followed the IPMSSG 2012 criteria[1]. However this three months duration merits 
further study as it is arbitrary. International collaborations are now required to unify 
treatment guidelines to inform on early prognostic markers and treatment effect in 
this rare demyelinating syndrome.  
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Table 1 – Patient characteristics  
Clinical parameters  Patients n=17 
Male, n (%) 9 (56) 
Age of onset, years (IQR) 6.1 (5.1-9.2) 
Caucasian, n (%) 13 (81) 
Autoimmune disease, n (%) 0  
Admission to ICU, n (%) 7 (41) 
Preceding event <4 weeks before onset, n (%) 
- Vaccination  
- Infection/fever 
 
- 5 (29) 
- 11 (65) 
CSF oligoclonal bands, n (%) 0/14  
MOG-Ab 16/17 








MRI Spine at baseline  12/15 (80%) 
Presenting symptoms  
Seizures, n (%) 7 (41) 
Vision disturbances, n (%) 6 (35) 
Autonomic features, n (%) 7 (41) 
Cranial nerves, n (%) 3 (18) 
Bulbar dysfunction, n (%) 1 (6) 
Sensory, n (%) 3/15 (20) 
Motor dysfunction, n (%) 9 (53) 
Cerebellar symptoms, n (%) 9 (53) 
Headache, n (%) 10 (59) 
Acute treatment, n (%) 
- IvMP 3-5 days 
- Dexamethasone 
- IvIG 5 days  
- Additional treatment  
o 2nd IvMP 3-5 days 
o 2nd IvIG 5 days 
13 (77) 
- 10/13 (77) 
- 2/13 (15) 
- 1/13 (8) 
- 7/13 (54) 
o 4/7  
o 3/7 
Outcome, n (%) 
- Residual deficits  
- Visual impairment 
- Visual acuity impairment  
- Visual field impairment 
- Colour vision 
- Cognitive impairment  
- Seizures 
 







Definitions. IQR: interquartile range. ICU: intensive care unit. CSF: cerebral 
spinal fluid. ADEM: acute disseminated encephalomyelitis. IvMP: intravenous 
methylprednisolone. IvIG: intravenous immunoglobulins. MOG-Ab: myelin 
oligodendrocyte glycoprotein antibodies (IgG subtype).  
* Baseline MRI brain performed within 3 months after onset of symptoms. a 
ADEM-like MRI: predominantly confluent, hazy and poorly demarcated 
involving both grey and white matter.bUnspecific lesions: non-specific white 
matter lesions not fulfilling MAGNIMS criteria for MS specific lesions. 
cUnavailable: patient was retrospectively identified. MRI was not assessable. 
However, the patient had encephalopathy at presentation and patient charts 

















Figure Caption and legend  
Figure 1 – ADEM-ON disease course and treatment. The disease course and 
given treatments per patient are shown in this figure. MRI images are displayed from 
patient 12. Onset MRI: bilateral multiple large and hazy lesions on FLAIR sequence. 
Relapse 1: MRI shows resolution of white matter lesions on FLAIR, and a thickened 
left optic nerve on T1 sequence without gadolinium enhancement. Relapse 3: relapse 
of ON without new T2 lesions.  
Abbreviations. ADEM: acute disseminated encephalomyelitis. ON: optic neuritis. P: 
oral prednisone. AZA: azathioprine. MMF: mycophenolate mofetil. CYC: 
cyclophosphamide. RTX: Rituximab. IvIG: intravenous immunoglobulins  
 
